Summary We evaluated the best route of administration of TNP-470, an angiogenesis inhibitor, by comparing the anti-tumour effects and toxicity following injection via the hepatic artery, the portal vein, or the jugular vein in a rabbit model of liver metastases. Following the injection of 1 x 106 VX2 carcinoma cells into the portal vein of rabbits, 50 mg of TNP-470 was injected continuously into the hepatic artery, portal vein, or jugular vein for 7 days. The number of tumours on the surface of the liver was counted 14 days following the start of the infusion, and the serum glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT) and total bilirubin concentrations were examined. In addition, a coloured silicon rubber was injected into the vessels of the liver to visualise the capillary networks around the tumours and assess the degree of suppression of angiogenesis by . The mean number of tumours following intra-arterial injection (17.5 ± 2.9) was significantly less than the control (237.0 ± 34.0) (P<0.05). The mean numbers of the tumours following intraportal (89.1 ± 16.0) and intravenous (140.6 ± 31.2) injection were both less than the controls (215.3 ± 45.5, 284.8 ± 55.4 respectively), but the differences were not significant. We conclude that intra-arterial injection of TNP-470 is the most effective method for preventing liver metastases in this model. Keywords: angiogenesis inhibitor; metastatic liver cancer; intra-arterial injection therapy
The prevention of haematogenous metastases, particularly to the liver, would profoundly improve the prognosis of most cancer patients. However, it is not yet known how to prevent or treat liver metastases. Chemotherapy usually is given for unresectable liver metastases, but several tumours are not sensitive to drugs currently available. Furthermore, most tumours develop resistance, and the toxicities of several agents are too great to permit prolonged treatment.
Because angiogenesis is essential for the proliferation of cancer cells, the inhibition of new blood vessel growth may be a useful way to prevent liver metastases (Ingber et al., 1990) . In addition, endothelial cells do not proliferate in adults except in a few parts of the genital organs (Kusaka et al., 1991) . Therefore, if one could inhibit the endothelial proliferation selectively, one could suppress tumour growth. A new synthetic analogue of fumagillin isolated from Aspergillus fumigatus, , is known to inhibit angiogenesis by inhibiting DNA synthesis in endothelial cells selectively, and to have an anti-tumour effect (Ingber et al., 1990; Kusaka et al., 1991) . We have already reported that intermittent intravenous injections of TNP-470 suppress the growth of VX2 tumour metastases in the livers of rabbits. In that study, the earlier TNP-470 was injected, the more effectively the liver metastases were suppressed (Suganuma et al., in press ). The purpose of the current study was to establish the best route of administration of TNP-470. We hypothesised that intra-arterial injection and intraportal injection would suppress liver metastases more effectively than would intravenous injection of this agent, based on our previous experiments with agents such as 5-fluorouracil (5-FU) (Takeuchi et al., 1994) . In addition, we visualised the small vessels generated around the liver tumours with a silicon rubber, to examine the angiogenesis inhibiting activity of TNP-470. -470 [O-(chloroacetyl-carbonyl) The third group received TNP-470 via the hepatic artery (group TA: eight rabbits), with controls, (group CA: seven rabbits). The polyethylene catheter was cannulated into the common hepatic artery from the left gastric artery, and the polyethylene catheters. Microfil (Canton Bio-Medical Products, Boulder. CO, USA) was injected through the catheters until the vessels appeared well filled. Orange Microfil (MV-117) was used for the hepatic artery, and yellow (MV-122) was used for the portal vein (Lin et al., 1984) . Low infusion pressures were used to prevent extravasation of the Microfil.
Materials and methods

TNP
The specimens were refrigerated overnight to cure the Microfil. A part of each specimen was fixed in 10% formalin, sectioned at the maximal diameter of the tumours and stained by hematoxylin-eosin for histological examination. The number of vessels inside or around the tumours was then counted. The remainder of each specimen was immersed sequentially in 25%, 50%, 75%, 95%, and absolute ethanol for 1-2 days each, and finally immersed in methylsalicylate. The specimens became transparent and the vessels' structure could be examined visually with a stereoscope.
All data are expressed as means ± standard errors. The results were analysed by Student's t-test. A P-value 0.05 was considered statistically significant. (Figure 2 ). The serum GOT and GPT concentrations were not higher in the TNP-470 injected groups than in the controls (Figures 3 and 4) . The total bilirubin was not elevated in any rabbit ( Figure 5 (Figure 8 ). We suggested that the differences in the density of the capillary networks between the TNP470 injected groups and the controls was caused by the angiogenesis inhibiting activity of TNP470.
Discus
Kusaka et al. (1991) have reported that a broad range of concentrations of TNP470, which is a synthetic analogue of fumagillin, a natural product of Aspergillus fumigatus, could selectively inhibit endothelial proliferation, with a subsequent anti-tumour effect. Several papers have previously described the anti-tumour effects of TNP470, but most of them used a single systemic bolus injection of TNP470 (Toi et al., 1993: Yanase et al.. 1993).
As TNP470 is cleared rapidly from the serum, we hypothesised that a continuous infusion of the drug would be more effective than intermittent administration. In spite of our expectations, continuous venous injection was no better than the intermittent injection reported previously. Today, chemotherapy for liver metastases is often administered through the hepatic artery. However, there is some evidence that in the first stage of metastasis, microemboli of tumour cells are nourished from the portal vein. It is controversial therefore whether the best route of administration of drugs to treat liver metastases is the portal vein or from the hepatic artery. In this study, the mean number of tumours in the intra-arterial injection group was significantly less than in the controls. The mean number of tumours in the intraportal and intravenous groups was less than in the controls, but the into the vessels around and inside black in this figure. Magnifidifferences were not significant. Almost all the tumours were within 7 mm in diameter. with a few tumours in both the treated groups and control groups over 10 mm in diameter (maximum 15 mm). Although we expected the tumours to be smaller in the groups receiving TNP-470, this was not the case. We do not know why a few tumours in the treated groups could grow so large, but one hypothesis is that the agent is not delivered homogeneously into the entire liver.
The current study indicates that arterial injection is the most effective route for treatment with TNP470. which is different from our previous report using 5-FU for the same experimental liver metastases (Takeuchi et al.. 1994) In our Microfil models, almost all of the tumour vessels orginated from the hepatic artery, and never from the portal vein. The number of vessels induced by tumours in the TNP-470 groups was much less than in the control groups, which again suggests that the anti-tumour effect of was secondary to the suppression of angiogenesis.
We evaluated the side effects of TNP-470 using weight loss, and serum GOT, GPT, and total bilirubin elevations as parameters. None of the TNP-470 injection groups had significant weight loss or significant liver disfunction compared with the controls. Therefore, the continuous administration of TNP-470 seems to have no severe adverse effects.
We conclude that the efficacy of TNP-470 is enhanced by intra-arterial administration.
